Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2011, Article ID 260191, 6 pages
http://dx.doi.org/10.4061/2011/260191
Clinical Study

Renal Function but Not Asymmetric Dimethylarginine Is Independently Associated with Retinopathy in Type 2 Diabetes

1Internal Medicine 1, Rudolfstiftung Hospital, 1030 Vienna, Austria
2Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
3Internal Medicine 5, Wilhelminen Hospital, 1160 Vienna, Austria
4Internal Medicine 2, Medical University of Vienna, 1090 Vienna, Austria
5Ophtalmology, Rudolfstiftung Hospital, 1030 Vienna, Austria

Received 15 November 2010; Accepted 3 March 2011

Academic Editor: H. O. Ventura

Copyright © 2011 Katarzyna Krzyzanowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. V. Van Hecke, J. M. Dekker, C. D. A. Stehouwer et al., “Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study,” Diabetes Care, vol. 28, no. 6, pp. 1383–1389, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Cheung, J. J. Wang, R. Klein, D. J. Couper, A. R. Sharrett, and T. Y. Wong, “Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study,” Diabetes Care, vol. 30, no. 7, pp. 1742–1746, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. Hiller, R. D. Sperduto, M. J. Podgor, F. L. Ferris III, and P. W. F. Wilson, “Diabetic retinopathy and cardiovascular disease in type II diabetics. The framingham heart study and the framingham eye study,” American Journal of Epidemiology, vol. 128, no. 2, pp. 402–409, 1988. View at Google Scholar · View at Scopus
  4. K. Krzyzanowska, F. Mittermayer, M. Wolzt, and G. Schernthaner, “Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes,” Diabetes Care, vol. 30, no. 7, pp. 1834–1839, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. L. Tarnow, P. Hovind, T. Teerlink, C. D. A. Stehouwer, and H. H. Parving, “Elevated pasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes,” Diabetes Care, vol. 27, no. 3, pp. 765–769, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Hanai, T. Babazono, I. Nyumura et al., “Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes,” Nephrology Dialysis Transplantation, vol. 24, no. 6, pp. 1884–1888, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. K. Krzyzanowska, F. Mittermayer, N. Shnawa et al., “Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria,” Diabetic Medicine, vol. 24, no. 1, pp. 81–86, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. T. Malecki, A. Undas, K. Cyganek et al., “Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes,” Diabetes Care, vol. 30, no. 11, pp. 2899–2901, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. “Early treatment diabeticretinopathy study design and baseline patient characteristics. ETDRS report number 7,” Ophthalmology, vol. 98, no. 5, pp. 741–756, 1991.
  10. “Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group,” Ophthalmology, vol. 98, no. 5, pp. 823–833, 1991.
  11. “Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group,” Ophthalmology, vol. 98, no. 5, pp. 786–806, 1991.
  12. M. D. Davis, M. R. Fisher, R. E. Gangnon et al., “Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early Treatment Diabetic Retinopathy Study Report #18,” Investigative Ophthalmology and Visual Science, vol. 39, no. 2, pp. 233–252, 1998. View at Google Scholar · View at Scopus
  13. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Google Scholar
  14. T. Teerlink, R. J. Nijveldt, S. De Jong, and P. A. M. Van Leeuwen, “Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography,” Analytical Biochemistry, vol. 303, no. 2, pp. 131–137, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. F. Mittermayer, K. Namiranian, J. Pleiner, G. Schaller, and M. Wolzt, “Acute Escherichia coli endotoxaemia decreases the plasma L-arginine/asymmetrical dimethylarginine ratio in humans,” Clinical Science, vol. 106, no. 6, pp. 577–581, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. P. D. Reaven, N. Emanuele, T. Moritz et al., “Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT),” Diabetes Care, vol. 31, no. 5, pp. 952–957, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. T. Kielstein, R. H. Böger, S. M. Bode-Böger et al., “Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease,” Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 170–176, 2002. View at Google Scholar · View at Scopus
  18. H. H. Parving, M. A. Gall, and F. S. Nielsen, “Dyslipidaemia and cardiovascular disease in non-insulin-dependent diabetic patients with and without diabetic nephropathy,” Journal of Internal Medicine, Supplement, vol. 236, no. 736, pp. 89–94, 1994. View at Google Scholar · View at Scopus
  19. R. G. Nelson, J. A. Wolfe, M. B. Horton, D. J. Pettitt, P. H. Bennett, and W. C. Knowler, “Proliferative retinopathy in NIDDM. Incidence and risk factors in Pima Indians,” Diabetes, vol. 38, no. 4, pp. 435–440, 1989. View at Google Scholar · View at Scopus
  20. M. Sugai, A. Ohta, Y. Ogata et al., “Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients,” Endocrine Journal, vol. 54, no. 2, pp. 303–309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. S. Edwards, D. B. Wilson, T. E. Craven et al., “Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study,” American Journal of Kidney Diseases, vol. 46, no. 2, pp. 214–224, 2005. View at Google Scholar
  22. T. Y. Wong, J. Coresh, R. Klein et al., “Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study,” Journal of the American Society of Nephrology, vol. 15, pp. 2469–2476, 2004. View at Google Scholar